Japanese company profile · 7776
CellSeed Inc.
English company name recorded in Japan's EDINET filer data.
Original Japanese company name: 株式会社セルシード
Name follows the English name recorded in EDINET filer data. English company name source
FY2025 · fiscal year ended December 2025Latest filing date: 2026-03-26What does this company do?
What does this company do?
In its FY2025 public filing, CellSeed Inc. reports Regenerative Medicine Support Project, Cell sheet regenerative medicine. The page shows business-level revenue and profit where the source disclosures support comparison.
CellSeed Inc.'s largest reported business by revenue in FY2025 was Regenerative Medicine Support Project.
FY2025 · fiscal year ended December 2025 · View original filing ↗ The source document may be in Japanese.
Reported company-wide figures
- Company revenue
- ¥83.68M ↗ FY2025 · fiscal year ended December 2025
- Operating profit
- −¥1.05B ↗ FY2025 · fiscal year ended December 2025
- Comparable margin
- -1250.2% ↗ FY2025 · fiscal year ended December 2025
JGAAP · Parent-only
Company profile
Identity
- Securities code
- 7776
- EDINET code
- E24158
- Corporate number
- 9011101031759
- Listing status
- Listed
- Industry (EDINET filer classification)
- Precision instruments
Location and fiscal year
- Headquarters
- 東京都江東区 · As filed in Japanese
- Fiscal year end
- 12month
- Latest fiscal year
- FY2025
- Accounting standard
- JGAAP
- P16 data snapshot
- 2026-11-07
Company size
- Employees (non-consolidated)
- 36 people (FY2025)
- Capital stock
- JPY 2.3 billion (FY2025)
Official information
- Latest annual securities report
- Latest annual securities report Opens in a new tab
Public information is organized and presented by P16. EDINET filer list (2026-11-07) Opens in a new tab · EDINET PDL 1.0 terms Opens in a new tab
Business structure
How does it make money?
| Business | Sales | Share of company sales | Operating profit | Margin |
|---|---|---|---|---|
| Regenerative Medicine Support Project | ¥81.8M ↗ | — | −¥104.79M ↗ | -128.1% |
| Cell sheet regenerative medicine | ¥1.88M ↗ | — | −¥722.98M ↗ | -38558.9% |
All values are in Japanese yen (JPY). No currency conversion is applied. FY2025 · fiscal year ended December 2025. Revenue and profit are shown only where the filing and data support a comparison. “—” means a comparable amount was not disclosed. We compare sales to outside customers for each business and the company as a whole, using the same filing, fiscal year and scope. Reported business sales may include sales between businesses. We leave the share blank when the figures cannot be matched.
Company revenue
Company-wide trend
Company revenue
JGAAP · Consolidated- FY2021
100.0 ¥161.67M
Company revenue
JGAAP · Parent-only- FY2022
65.4 ¥126.43M - FY2023
98.4 ¥190.13M - FY2024
100.0 ¥193.28M - FY2025
43.3 ¥83.68M
Company operating profit
JGAAP · Consolidated- FY2021
100.0 −¥864.68M
Company operating profit
JGAAP · Parent-only- FY2022
71.0 −¥743.22M - FY2023
66.7 −¥697.78M - FY2024
80.9 −¥846.38M - FY2025
100.0 −¥1.05B
Only reported years are shown. Missing years are left blank; accounting standards and scopes are kept in separate series.
Reported Sales by business over time
Reported Sales by business over time
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Regenerative Medicine Support Project | ¥147.82M | ¥116.01M | ¥182.33M | ¥192.06M | ¥81.8M |
| Cell sheet regenerative medicine | ¥13.85M | ¥10.41M | ¥7.8M | ¥1.22M | ¥1.88M |
All amounts are in Japanese yen (JPY). Each figure links to the original Japanese filing. Blank cells indicate no comparable figure was disclosed. Business figures may not add up to consolidated figures.
What is growing?
What is growing?
No comparable reported revenue growth is available.
What has changed?
What has changed?
A five-year business-mix comparison is not shown because the available filings do not provide five comparable years on the same basis.
Source
Company profile
These scores summarize company characteristics using public filings. Comparison groups vary by measure. Higher is not always better.
- Growth—No comparable data
- ProfitabilityPosition among all companies with available values in the fixed reference data.FY2025
0 - Business concentration—No comparable data
- Business change—No comparable data
- Cash generation—No comparable data
- Growth persistencePeer-position scoreFY2022→FY2023, FY2023→FY2024, FY2024→FY2025
29
Source
Public filing
FY2025 · fiscal year ended December 2025
The source document may be in Japanese.
Filing ID: S100XUKD
View original filing ↗